Samantha Peacock

Samantha’s experience includes advising:

Venture Capital – Investor Side

• atai Life Sciences on its strategic investment in, and subsequent acquisition of, Beckley Psytech, a private clinical-stage biotechnology company
• Patient Square Capital on its US$226.5 million lead investment in Apollo Therapeutics’ Series C financing round
• Octopus Ventures on multiple investments, including in Menwell (t/a Manual), Pencil Biosciences, Vira Health, Awell Health, and Touchlab, spanning from pre-seed to Series B
• Hoxton Ventures on its lead investments in Skin Analytics, Bother, Slice, and Luminary ROLI
• Novo on its Series D and E investments in Quanta Dialysis Technologies, a commercial-stage dialysis device company
• Citi Ventures on its investment in GoHenry’s US$40 million funding round
• GIC, JP Morgan, and HSBC’s Venture Capital Fund on their Series B+ investments in Miotech, an ESG data startup

Venture Capital – Company Side

• OrganOx, a leading organ medical technology company, on its US$142 million primary and secondary equity financing round, led by HealthQuest Capital, BGF, and Lauxera Capital Partners
• Verdiva Bio, a clinical-stage biopharmaceutical company, on its US$410 million Series A financing, led by Forbion and General Atlantic
• WorldRemit on its US$292 million Series E funding round
• Toqio on its seed funding round, led by Seaya and Speedinvest
• LifeScore on its £11 million Series A financing, led by Octopus Ventures and Warner Music Group
• Aztec Network on its Series B and A funding rounds, led by a16z and Paradigm, respectively
• Fertifa Limited, the UK’s first and leading reproductive healthcare benefits provider and provider of a next-generation fertility clinic, on its seed funding round, led by Passion Capital

Healthcare & Life Sciences M&A

• OrganOx on its US$1.5 billion sale to Terumo shortly after its US$142 million equity financing round
• BC Partners on its sale of a majority stake in Synthon, a leading international pharmaceutical company, to Goldman Sachs Alternatives
• Novo Holdings on its acquisition of the Norwegian fish genetics company Benchmark Genetics from Benchmark Holdings plc
• Norgine, a European specialty pharmaceutical company, on selling a controlling stake to Goldman Sachs Asset Management
• Lindsay Goldberg on portfolio company MMS’ acquisition of data science company Exploristics
• TPG on acquiring Doc Generici, a leading Italian generics company
• Alliance Pharma on acquiring US scar treatment brand ScarAway
• Acino on acquiring approximately 30 products across Takeda’s primary care portfolio in MENA and Ukraine
• Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, on CVC’s US$703 million acquisition women’s healthcare assets from Teva
• TLS Beta on acquiring a 30% stake in Stamford Devices, an Ireland-based provider of medical device and drug delivery services and holding company for Aerogen
• Actavis on its:
  • £306 million acquisition of Auden Mckenzie, a pharmaceutical company that develops, licenses, and markets generic medicines and proprietary brands, making Actavis the largest generics company in the UK
  • Divestment of part of its Western European generics sale and marketing business to Aurobindo*
  • £603 million divestment of its UK and Ireland business by Teva to Intas*

*Matter handled prior to joining Latham